|
04/07/2025
|
07:00
|
Imfinzi approved in the EU for bladder cancer
|
RNS
|
|
01/07/2025
|
15:00
|
Total Voting Rights
|
RNS
|
|
24/06/2025
|
07:00
|
Datroway approved in US for EGFRm lung cancer
|
RNS
|
|
17/06/2025
|
11:45
|
Holding(s) in Company
|
RNS
|
|
13/06/2025
|
09:30
|
AstraZeneca enters into collaboration with CSPC
|
RNS
|
|
12/06/2025
|
15:00
|
Director/PDMR Shareholding
|
RNS
|
|
06/06/2025
|
07:00
|
Fixed-duration Calquence approved in EU for 1L CLL
|
RNS
|
|
02/06/2025
|
15:05
|
Block listing Interim Review
|
RNS
|
|
02/06/2025
|
15:00
|
Total Voting Rights
|
RNS
|
|
27/05/2025
|
07:00
|
Imfinzi recommended in EU for bladder cancer
|
RNS
|
|
23/05/2025
|
10:00
|
Director/PDMR Shareholding
|
RNS
|
|
21/05/2025
|
13:45
|
Director Declaration
|
RNS
|
|
20/05/2025
|
07:00
|
Acquisition of EsoBiotec completed
|
RNS
|
|
09/05/2025
|
07:00
|
Imfinzi improved DFS in early bladder cancer
|
RNS
|
|
07/05/2025
|
07:30
|
Enhertu improved pCR in early-stage breast cancer
|
RNS
|
|
06/05/2025
|
07:00
|
Calquence combination approved in EU for 1L MCL
|
RNS
|
|
02/05/2025
|
07:00
|
Breztri met primary endpoints in Ph3 asthma trials
|
RNS
|
|
01/05/2025
|
16:00
|
Director/PDMR Shareholding
|
RNS
|
|
01/05/2025
|
15:00
|
Total Voting Rights
|
RNS
|
|
29/04/2025
|
07:10
|
Fixed-duration Calquence recommended in EU for CLL
|
RNS
|
|
29/04/2025
|
07:05
|
Update on CAPItello-280 Phase III trial
|
RNS
|
|
29/04/2025
|
07:00
|
1st Quarter Results
|
RNS
|
|
22/04/2025
|
07:00
|
Enhertu combination improved PFS in 1L HER2+ mBC
|
RNS
|
|
11/04/2025
|
17:30
|
Result of AGM
|
RNS
|
|
04/04/2025
|
07:05
|
Imfinzi approved in EU for AEGEAN
|
RNS
|
|
04/04/2025
|
07:00
|
Enhertu approved in EU in post-ET breast cancer
|
RNS
|
|
01/04/2025
|
15:00
|
Total Voting Rights
|
RNS
|
|
31/03/2025
|
07:05
|
Calquence recommended for EU approval in 1L MCL
|
RNS
|
|
31/03/2025
|
07:00
|
Imfinzi approved in the US for bladder cancer
|
RNS
|
|
21/03/2025
|
10:58
|
AZN invests $2.5bn in Beijing R&D & manufacturing
|
RNS
|
|
17/03/2025
|
07:10
|
Eneboparatide Phase III trial met primary endpoint
|
RNS
|
|
17/03/2025
|
07:05
|
Imfinzi approved in EU for limited-stage SCLC
|
RNS
|
|
17/03/2025
|
07:00
|
AstraZeneca to acquire EsoBiotec
|
RNS
|
|
12/03/2025
|
18:00
|
Holding(s) in Company
|
RNS
|
|
07/03/2025
|
15:00
|
Director/PDMR Shareholding
|
RNS
|
|
07/03/2025
|
11:00
|
Notice of AGM
|
RNS
|
|
07/03/2025
|
07:00
|
Imfinzi improved EFS in early-stage gastric cancer
|
RNS
|
|
06/03/2025
|
15:00
|
Director/PDMR Shareholding
|
RNS
|
|
05/03/2025
|
15:00
|
Director/PDMR Shareholding
|
RNS
|
|
03/03/2025
|
15:00
|
Total Voting Rights
|
RNS
|
|
03/03/2025
|
07:00
|
Imfinzi recommended for EU approval for AEGEAN
|
RNS
|
|
28/02/2025
|
13:00
|
Enhertu recommended in EU in post-ET breast cancer
|
RNS
|
|
26/02/2025
|
07:00
|
Camizestrant improved PFS in 1L HR+ breast cancer
|
RNS
|
|
19/02/2025
|
07:00
|
Filing of Form 20-F with SEC
|
RNS
|
|
18/02/2025
|
14:00
|
Holding(s) in Company
|
RNS
|
|
18/02/2025
|
11:00
|
Annual Financial Report
|
RNS
|
|
18/02/2025
|
07:00
|
Directorate Change
|
RNS
|
|
06/02/2025
|
07:00
|
Final Results
|
RNS
|
|
03/02/2025
|
17:00
|
Total Voting Rights
|
RNS
|
|
03/02/2025
|
07:00
|
Imfinzi recommended for EU approval for LS-SCLC
|
RNS
|